Biohaven Ltd. reports results for the quarter ended June 30 - Earnings Summary

Biohaven

10/08/2026 21:20

Biohaven Ltd. BHVN.N reported a quarterly adjusted loss of 91 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $-1.94.  The mean expectation of seventeen analysts for the quarter was for a loss of 73 cents per share. Wall Street expected results to range from -97 cents to -44 cents per share.
Reported revenue was zero​; analysts expected $535.46 thousand. 
Biohaven Ltd.'s reported EPS for the quarter was a loss of 91 cents​.
The company reported a quarterly loss of $137.31 million.
Biohaven Ltd. shares had fallen by 1.5% this quarter and gained 29.8% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 1.9% in the last three months.​ 
In the last 30 days, one analyst negatively revised an earnings estimate
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy," 3 "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" 
Wall Street's median 12-month price target for Biohaven Ltd. is $20.50, about 28.5% above its last closing price of $14.66
This summary was machine generated from LSEG data August 10 at 08:20 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.73
-0.91
Missed
Mar. 31 2026 
-0.83
-0.88
Missed
Dec. 31 2025 
-1.29
-1.21
Beat
Sep. 30 2025 
-1.89
-1.64
Beat